| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
3,020 |
2,698 |
$119K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
3,193 |
2,988 |
$113K |
| 80053 |
Comprehensive metabolic panel |
15,757 |
11,228 |
$79K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
20,451 |
12,102 |
$58K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,802 |
1,585 |
$39K |
| 84484 |
|
7,412 |
5,232 |
$38K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
7,260 |
3,148 |
$30K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,168 |
1,066 |
$26K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,163 |
1,061 |
$26K |
| 83735 |
|
7,565 |
3,915 |
$26K |
| 87040 |
|
1,633 |
1,191 |
$20K |
| 83880 |
|
1,821 |
1,377 |
$17K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
912 |
856 |
$16K |
| 83690 |
|
4,442 |
3,712 |
$15K |
| 83605 |
|
2,592 |
1,528 |
$14K |
| 81001 |
|
7,133 |
6,267 |
$11K |
| 81025 |
|
5,479 |
4,775 |
$11K |
| 82805 |
|
898 |
347 |
$10K |
| 85730 |
|
2,831 |
2,103 |
$10K |
| 85027 |
|
3,295 |
1,522 |
$9K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,809 |
1,578 |
$9K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
513 |
471 |
$9K |
| 87641 |
|
372 |
334 |
$8K |
| 85610 |
|
3,917 |
2,598 |
$7K |
| 87430 |
|
845 |
807 |
$7K |
| 87186 |
|
889 |
721 |
$6K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
239 |
201 |
$5K |
| 85379 |
|
1,377 |
900 |
$5K |
| 86901 |
|
1,497 |
1,240 |
$3K |
| 84702 |
|
680 |
570 |
$3K |
| 84105 |
|
2,019 |
695 |
$3K |
| 86900 |
|
1,493 |
1,236 |
$3K |
| 86850 |
|
851 |
672 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
804 |
729 |
$2K |
| 84443 |
Thyroid stimulating hormone (TSH) |
286 |
251 |
$2K |
| 82728 |
|
589 |
299 |
$2K |
| 81003 |
|
1,858 |
1,693 |
$2K |
| 87081 |
|
650 |
625 |
$2K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
23 |
21 |
$2K |
| 82248 |
|
1,251 |
787 |
$2K |
| 87210 |
|
601 |
538 |
$1K |
| 86140 |
|
581 |
272 |
$1K |
| 80061 |
Lipid panel |
432 |
379 |
$1K |
| 86769 |
|
68 |
62 |
$1K |
| 82607 |
|
193 |
158 |
$1K |
| 87449 |
|
132 |
107 |
$1K |
| 85651 |
|
429 |
299 |
$954.50 |
| 84145 |
|
361 |
295 |
$930.81 |
| 87420 |
|
105 |
101 |
$845.01 |
| 80069 |
|
188 |
57 |
$724.20 |
| 87631 |
|
13 |
12 |
$687.70 |
| 82140 |
|
140 |
65 |
$580.99 |
| 84703 |
|
130 |
122 |
$464.41 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
22 |
20 |
$412.46 |
| 87486 |
|
23 |
21 |
$412.20 |
| 87581 |
|
23 |
21 |
$412.20 |
| 84100 |
|
154 |
61 |
$356.22 |
| 87340 |
|
51 |
51 |
$337.50 |
| 85384 |
|
115 |
44 |
$312.52 |
| 82550 |
|
124 |
71 |
$297.05 |
| 83615 |
|
164 |
77 |
$296.04 |
| 82746 |
|
62 |
46 |
$292.23 |
| 87205 |
|
151 |
107 |
$287.00 |
| 83550 |
|
62 |
52 |
$248.24 |
| 83540 |
|
64 |
53 |
$191.40 |
| 80076 |
|
63 |
56 |
$186.47 |
| 83520 |
|
26 |
13 |
$145.82 |
| 87077 |
|
199 |
157 |
$139.52 |
| 87070 |
|
33 |
26 |
$114.70 |
| 86920 |
|
36 |
13 |
$96.35 |
| 86704 |
|
12 |
12 |
$86.35 |